OC-0535: A Prospective Multi-Center Study of Plasma EBV DNA Monitoring in Nasopharyngeal Carcinoma

J.C. Lin,W.Y. Wang,S.W. Leung,H.H.W. Chen,C.J. Huang,L.L. Ting

DOI: https://doi.org/10.1016/s0167-8140(15)40530-4

IF: 6.901

2015-01-01

Radiotherapy and Oncology

Abstract:3rd ESTRO Forum 2015 S259 the OTT in the postoperative setting is less clear.Therefore, the main objective of this phase III study was to determine the value of reduction of the OTT of postoperative radiotherapy in high risk patients primarily treated with surgery.Materials and Methods: Patients with HNSCC treated with curative surgery and with high risk factors for locoregional recurrence (i.e., positive surgical margins and/or extranodal spread) were randomly assigned to receive either conventional postoperative radiotherapy (CON-RT) at 2 Gy/fraction/day, 5 days/week to 66 Gy/33 fractions/7 weeks or postoperative accelerated radiotherapy (POPART) with 2 Gy/fraction/day, 5 days per week, to 20 Gy followed by 1.8 Gy/fraction/day and 1.3 Gy/fraction per day to a boost field as a second daily treatment to 66.5 Gy/40 fractions/5 weeks.The primary endpoint was locoregional tumor control (LRC).Secondary endpoints were overall survival (OS), progression-free survival (PFS), acute and late toxicity and quality of life.Results: From November 2004 to August 2009, 148 patients were enrolled in the study (74 pts for CON-RT and 74 pts for POPART).The median follow up time was 6.2 years.The two study-arms were well balanced with regard to the most important prognostic factors.No significant differences were noted with regard to acute and late toxicity, although there was a trend towards more use of pain medication among patients treated with POPART.At 3 years, the LRC rate was 76.5% (95% CI: 67.0-87.4)after POPART compared to 74.2% (95% CI: 64.6-85.0)with CON-RT (HR: 0.75, CI 0.40-1.43;p=0.39).No difference was found with regard to PFS (p=0.16) with a HR of 0.74 (95% CI: 0.49 -1.13).The medians were 42.6 (95%CI: 31-78.3)months for CON-RT and 60.5 (95%CI: 34.6-NA) for POPART.The DFS probability at 8 years was 43.8% for CON-RT (95% CI: 33.8-57.0)and 51% POPART (95% CI: 40.7-63.8).No statistical difference was noted in the long term between the two arms.The 8-year overall survival rate was 46.0% with POPART compared to 33.1% with CON-RT (HR:0.82,CI 0.53-1.28;p=0.39).Conclusions: A reduction in the OTT of postoperative radiotherapy in patients with HNSCC with adverse factors for locoregional failure does not improve outcome in terms of LRC, PFS and OS.